由 John R. Fischer
, Senior Reporter | April 26, 2021
German researchers are building what they say is the first prototype of a proton therapy system capable of tracking moving tumors with MR imaging, potentially paving the way for better targeted treatment.
"Real-time magnetic resonance imaging has the unique ability to provide excellent soft-tissue contrast in addition to fast imaging that captures organ motion," Dr. Aswin Hoffmann, research group leader of experimental MR-integrated Proton Therapy, Institute of Radiooncology – OncoRay, told HCB News. "Typical examples are cancers that could benefit are those of the liver, pancreas, oesophagus, rectum, kidney, adrenal and cervix."
To see if real-time imaging could synchronize the proton beam to tumor motion, the researchers combined a rotating, open low-field 0.22 Tesla MR scanner designed by ASG Superconductors for the LINAC-MR system from Alberta Health Services, with an actively scanned proton beam at OncoRay. The results showed strong MR image quality during irradiation with a static beam.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Hoffmann plans to build a prototype that may be used clinically at some point. ASG Superconductors will produce the mid-field-strength open 0.5 Tesla MR device, which will be specifically adapted to the requirements of real-time MR-guided radiation therapy by the Alberta Health Services LINAC-MR group and its spin-off company MagnetTx Oncology Solutions. Engineers at MagnetTx Oncology Solutions are developing the gantry required to rotate the MR scanner and the image processing methods for automatically tracking tumors in real time.
"New capabilities provided by MR-integrated proton therapy include an increased targeting accuracy for the treatment of moving tumors, an expansion of the range of possible organs which can be targeted with increased precision and less normal-tissue side effects, and last but not least, this technique will inform the repurposing of radiation therapy to address other pathologies, such as arrhytmic myocardial tissue ablation with highest precision comparable to surgical procedures," Hoffmann told HCB News.
The design and manufacturing of the device is underway, with the team planning to combine it with the actively scanned experimental proton beamline at the OncoRay facility in summer 2022.